150 related articles for article (PubMed ID: 11989174)
1. [HIV resistance testing. Introduction of a new technique].
Dragsted UB; Benfield TL
Ugeskr Laeger; 2002 Apr; 164(17):2263-7. PubMed ID: 11989174
[TBL] [Abstract][Full Text] [Related]
2. [Drug resistance in antiretroviral therapy of HIV infection].
Oette M; Häussinger D
Med Klin (Munich); 2003 Dec; 98(12):692-9. PubMed ID: 14685670
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic drug monitoring and human immunodeficiency virus (HIV) antiretroviral therapy.
Justesen US
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):20-31. PubMed ID: 16433887
[TBL] [Abstract][Full Text] [Related]
4. HIV therapy after treatment interruption in patients with multiple failure and more than 200 CD4+ T lymphocyte count.
Jaafar A; Massip P; Sandres-Sauné K; Souyris C; Pasquier C; Aquilina C; Izopet J
J Med Virol; 2004 Sep; 74(1):8-15. PubMed ID: 15258962
[TBL] [Abstract][Full Text] [Related]
5. Genotypic resistance tests in the management of the HIV-infected patient at virological failure.
Aceti A; Carosi G
Scand J Infect Dis Suppl; 2003; 106():61-6. PubMed ID: 15000587
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.
Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U
Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534
[TBL] [Abstract][Full Text] [Related]
7. Genotypic resistance tests for the clinical management of patients with primary HIV infection.
Narciso P; Lazzarin A
Scand J Infect Dis Suppl; 2003; 106():66-70. PubMed ID: 15000588
[TBL] [Abstract][Full Text] [Related]
8. Successful application of laboratory tools for the detection of HIV drug resistance in routine clinical care in Georgia.
Chkhartishvili N; Dvali N; Gochitashvili N; Sharvadze L; Tsertsvadze T
Georgian Med News; 2008 Dec; (165):16-22. PubMed ID: 19124911
[TBL] [Abstract][Full Text] [Related]
9. [HIV-1 resistance against antiretroviral agents].
Asjø B; Ulvestad E
Tidsskr Nor Laegeforen; 2001 Nov; 121(29):3421-4. PubMed ID: 11826790
[TBL] [Abstract][Full Text] [Related]
10. [Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005].
Oette M; Kaiser R; Däumer M; Fätkenheuer G; Rockstroh JK; Knechten H; Mitrenga D; Beerenwinkel N; Sagir A; Pfister H; Häussinger D
Dtsch Med Wochenschr; 2007 May; 132(18):977-82. PubMed ID: 17457780
[TBL] [Abstract][Full Text] [Related]
11. Genotypic and phenotypic resistance patterns in early-stage HIV-1-infected patients failing initial therapy with stavudine, didanosine and nevirapine.
Vidal C; Arnedo M; Garcia F; Mestre G; Plana M; Cruceta A; Capon A; Gallart T; Miro JM; Pumarola T; Gatell JM
Antivir Ther; 2002 Dec; 7(4):283-7. PubMed ID: 12553483
[TBL] [Abstract][Full Text] [Related]
12. Genotypic drug resistance and long-term mortality in patients with triple-class antiretroviral drug failure.
Lohse N; Jørgensen LB; Kronborg G; Møller A; Kvinesdal B; Sørensen HT; Obel N; Gerstoft J;
Antivir Ther; 2007; 12(6):909-17. PubMed ID: 17926645
[TBL] [Abstract][Full Text] [Related]
13. Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097).
Delaugerre C; Peytavin G; Dominguez S; Marcelin AG; Duvivier C; Gourlain K; Amellal B; Legrand M; Raffi F; Costagliola D; Katlama C; Calvez V
J Med Virol; 2005 Nov; 77(3):345-50. PubMed ID: 16173015
[TBL] [Abstract][Full Text] [Related]
14. Genotypic resistance tests for the management of the HIV-infected pregnant woman.
Bassetti D; Cargnel A
Scand J Infect Dis Suppl; 2003; 106():70-4. PubMed ID: 15000589
[TBL] [Abstract][Full Text] [Related]
15. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
[TBL] [Abstract][Full Text] [Related]
16. Persistence of HIV-1 drug resistance mutations and emergence during antiretroviral treatment interruption: considerations from a clinical case.
Torti C; Moretti F; Uccelli MC; Tirelli V; Quiros-Roldan E; Gargiulo F; Carosi G
Med Sci Monit; 2003 Apr; 9(4):CS16-9. PubMed ID: 12709675
[TBL] [Abstract][Full Text] [Related]
17. Surveillance of genotypic resistance mutations in chronic HIV-1 treated individuals after completion of the National Access to Antiretroviral Program in Thailand.
Sukasem C; Churdboonchart V; Chasombat S; Kohreanudom S; Watitpun C; Pasomsub E; Piroj W; Tiensuwan M; Chantratita W
Infection; 2007 Apr; 35(2):81-8. PubMed ID: 17401711
[TBL] [Abstract][Full Text] [Related]
18. Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen.
Hatano H; Hunt P; Weidler J; Coakley E; Hoh R; Liegler T; Martin JN; Deeks SG
Clin Infect Dis; 2006 Nov; 43(10):1329-36. PubMed ID: 17051502
[TBL] [Abstract][Full Text] [Related]
19. GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy.
Bossi P; Peytavin G; Ait-Mohand H; Delaugerre C; Ktorza N; Paris L; Bonmarchand M; Cacace R; David DJ; Simon A; Lamotte C; Marcelin AG; Calvez V; Bricaire F; Costagliola D; Katlama C
HIV Med; 2004 Sep; 5(5):352-9. PubMed ID: 15369510
[TBL] [Abstract][Full Text] [Related]
20. Genotypic resistance tests for the management of postexposure prophylaxis.
Puro V
Scand J Infect Dis Suppl; 2003; 106():93-8. PubMed ID: 15000596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]